Evaluation of the Effect of Metformin on Breast Fibrocystic Changes

Tehran University of Medical Sciences0 个研究点目标入组 148 人开始时间: 待定最近更新: 2018年11月5日

试验速览

暂无简介。

•Body mass index greater than 29.9 kg / m2
•Use of hormonal medications (such as estrogen, progesterone, GnRH agonist, GnRH antagonist, clomiphene, tamoxifen, letrozole, danazol, contraceptive pills, progesterone IUDs, DHEA) and drugs that affect metabolic status, such as weight, glucose, and lipid-lowering agents During the study or three months before the study began
•Hormonal disorders and metabolic diseases such as hypo or hyperthyroidism, metabolic syndrome, diabetes, severe hyperlipidemia, galactorrhea
•Proven or suspected pregnancy and lactation during the intervention
•Other medical conditions, such as cardiovascular disease, epilepsy, renal or hepatic disorders
•Contraindications for metformin use (such as hypersensitivity to biguanides, acidemia, heart disease, alcohol consumption, gastroparesis, hepatic disease, hyperthyroidism or hypothyroidism, severe iron deficiency anemia, renal impairments)
•History of unwanted and intolerable side effects of metformin (such as abdominal pain, chest pain, chills, cholestasis, diarrhea, dizziness, increased liver enzymes, severe headache, hepatitis, hypoglycemia, megaloblastic anemia, myalgia, nausea, Palpitations, rash, rash, vomiting)

发起方